Merck’s Gardasil vaccine is now indicated for the prevention of genital warts (condyloma acuminata) caused by human papillomavirus (HPV) types 6 and 11 in boys and men 9 through 26 years of age. Gardasil is currently approved for use in girls and women 9 through 26 years of age for preventing cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; precancerous lesions caused by types 6, 11, 16, and 18; and genital warts caused by types and 11.
Most genital warts are caused by HPV infection. In a randomized trial, for males who were not infected by HPV types 6 and 11 at the start of the study, Gardasil was nearly 90% effective in preventing genital warts caused by infection with these HPV types.
In a randomized trial, for males who were not infected by types 6 and 11 at the start of the study, Gardasil was almost 90% effective in preventing genital warts caused by infection with these HPV types.
Gardasil is given as three injections over a six-month period. Source: FDA, Oct 19, 2009
